Enhancement of radiation therapy by vascular targeting agents

Current Opinion in Investigational Drugs

Volumn 3, Issue 11, 2002, Pages 1660-1665

  Siemann, Dietmar W ^a   Horsman, Michael R ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Radiotherapy; Tumor vasculature; Vascular targeting agent

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ANG 453; ANTINEOPLASTIC AGENT; COMBRETASTATIN A4 PHOSPHATE; MITOFLAXONE; N ACETYLCOLCHINOL PHOSPHATE; PRODRUG; SERINE 2 METHOXY 5 [2 (3,4,5 TRIMETHOXYPHENYL)VINYL]ANILIDE; TIRAPAZAMINE; TUBULIN BINDING AGENT; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BLOOD VESSEL FUNCTION; BLOOD VESSEL PARAMETERS; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONSERVATIVE TREATMENT; DRUG ACTIVITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG STRUCTURE; HUMAN; NUTRIENT SUPPLY; OXYGEN TRANSPORT; PHYSIOLOGY; REVIEW; SIDE EFFECT; SOLID TUMOR; TARGET ORGAN; TREATMENT OUTCOME; TUMOR DIFFERENTIATION; TUMOR MODEL; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM; WASTE COMPONENT REMOVAL;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; ORGANOPHOSPHORUS COMPOUNDS; XANTHENES; XANTHONES;

EID: 0036881356     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Ausprunk D, Folkman J: Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc Res (1977) 14(1):53-65.
2. Folkman J: How is blood vessel growth regulated in normal and neoplastic tissue? Cancer Res (1986) 46(2):467-473.
3. Hahnfeldt P, Panigrahy D, Folkman J, Hlatky L: Tumor development under angiogenic signaling: A dynamical theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res (1999) 59(19):4770-4775. Comprehensive overview of tumor angiogenesis.
4. Tannock IF: Population kinetics of carcinoma cells, capillary endothelial cells, and fibroblasts in a transplanted mouse mammary tumor. Cancer Res (1970) 30(10):2470-2476.
5. Vaupel P, Kallinowski F, Okunieff P: Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review. Cancer Res (1989) 49(23):6449-6465.
6. Vaupel P, Thews O, Hoeckel M: Tumor oxygenation: Characterization and clinical implications. In: Erythropoietin in Cancer Supportive Treatment. Smyth JF, Boogaerts MA, Ehmer BR (Eds), Marcel Dekker Inc, NY, USA (1996):205-239. A critical review of factors influencing tumor oxygenation.
7. 2 pedicts survival in advanced cancer of the uterine cervix. Radiother Oncol (1993) 264(1):45-50. Clinical demonstration that tumor hypoxia has a negative impact on radiotherapy.
8. Okunieff P, Hoeckel M, Dunphy EP, Schlenger K, Knoop C, Vaupel P: Oxygen tension distribution are sufficient to explain the local response of human breast tumors treated with radiation alone. Int J Radiat Oncol Biol Phys (1993) 26(4):631-636.
9. Brizel DM, Rosner GL, Harrelson J, Prosnitz LR, Dewhirst MW: Pretreatment oxygenation profiles of human soft tissue sarcomas. Int J Radiat Oncol Biol Phys (1994) 30(3):635-642.
10. Nordsmark M, Overgaard M, Overgaard J: Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol (1996) 41(1):31-39.
11. Brizel DM, Dodge RK, Clough RW, Dewhirst MW: Oxygenation of head and neck cancer: Changes during radiotherapy and impact on treatment outcome. Radiother Oncol (1999) 53(2):113-117.
12. 2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix. Radiother Oncol (1999) 53(2):99-104.
13. Walenta S, Schroeder T, Mueller-Klieser W: Metabolic mapping with bioluminescence: Basic and clinical relevance. Biomol Eng (2002) 18(6):249-262.
14. Durand RE: Keynote address: The influence of microenvironmental factors on the activity of radiation and drugs. Int J Radiat Oncol Biol Phys (1991) 20(2):253-258. Review describing the role of the tumor microenvironment in chemotherapy.
15. Siemann DW: Modification of chemotherapy by nitroimidazoles. Int J Radiat Oncol Biol Phys (1984) 10(9):1585-1594.
16. Sartorelli AC: Therapeutic attack of hypoxic cells of solid tumors: Presidential address. Cancer Res (1988) 48(4):775-778.
17. Chaplin DJ, Horsman MR, Trotter MJ, Siemann DW: Therapeutic significance of micorenvironment factors. In: Medical Radiology: Blood Perfusion and Microenvironment of Human Tumours. Molls M, Vaupel (Eds), Springer-Verlag, Heidelberg, Germany (1998):133-143.
18. Young SD, Marshall RS, Hill RP: Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells. Proc Natl Acad Sci USA (1988) 85(24):9533-9537.
19. Hill RP: Tumor progression: Potential role of unstable genomic changes. Cancer Metastasis Rev (1990) 9(2):137-147.
20. Giaccia AJ: Hypoxic stress proteins: Survival of the fittest. Semin Radiat Oncol (1996) 6(1):46-58. Review describing the microenvironment's effect on tumor progression and genomic changes.
21. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ: Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature (1996) 379(6560):88-91.
22. De Jaeger K, Kavanagh MC, Hill RP: Relationship of hypoxia to metastatic ability in rodent tumours. Br J Cancer (2001) 84(9):1280-1285.
23. Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR, Dewhirst MW: Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res (1996) 56(5):941-943.
24. Starnes CO: Coley's toxins in perspective. Nature (1992) 357(6373):11-12.
25. Denekamp J: Vasculature as a target for tumour therapy. In: Progress in Applied Microcirculation. Hammersen F, Hudlicka O (Eds), Karger AG, Basel, Switzerland (1984) 4:28-38.
26. Denekamp J: Review article: Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol (1993) 66(783):181-196. Discussion of the fundamental basis of the vascular targeting concept.
27. Chaplin DJ, Pettit GR, Hill SA: Anti-vascular approaches to solid tumour therapy: Evaluation of combretastatin A4 phosphate. Anticancer Res (1999) 19(1A):189-195.
28. Chaplin DJ, Dougherty GJ: Tumour vasculature as a target for cancer therapy. Br J Cancer (1999) 80(Suppl 1):57-64. Description of various approaches that may be used in targeting tumor blood vessels.
29. Zwi LJ, Baguley BC, Gavin JB, Wilson WR: Blood flow failure as a major determinant in the antitumor action of flavone acetic acid. J Natl Cancer Inst (1989) 81(13):1005-1013.
30. Siemann DW, Warrington KH, Horsman MR: Targeting tumor blood vessels: An adjuvant strategy for radiation therapy. Radiother Oncol (2000) 57(1):5-12. Review outlining the basis for combining antivascular and anti-angiogenic approaches with radiation in cancer therapy.
31. Blakey DC, Westwood FR, Walker M, Hughes GD, Davis PD, Ashton SE, Ryan AJ: Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res (2002) 8(6):1974-1983.
32. Ching LM, Joseph WR, Baguley BC: Antitumour responses to flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid in immune deficient mice. Br J Cancer (1992) 66(1):128-130.
33. Laws AL, Matthew AM, Double JA, Bibby MC: Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer (1995) 71(6):1204-1209.
34. Rewcastle GW, Atwell GJ, Li ZA, Baguley BC, Denny WA: Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. J Med Chem (1991) 34(1):217-222.
35. Cliffe S, Taylor ML, Rutland M, Baguley BC, Hill RP, Wilson WR: Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid. Int J Radiat Oncol Biol Phys (1994) 29(2):373-377.
36. Ching LM, Joseph Wr, Crosier KE, Baguley BC: Induction of tumor necrosis factor-α messenger RNA in human and murine cells by the flavone acetic analogue 5,6-dimethylxanthenone-4-acetic acid (NSC64088). Cancer Res (1994) 54(4):870-872.
37. Philpott M, Baguley BC, Ching LM: Induction of tumour necrosis factor-α by single and repeated doses of the antitumor agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol (1995) 36(2):143-148. Description of the mechanism of action of vascular targeting agent DMXAA.
38. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ: Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res (1997) 57(10):1829-1834.
39. Li L, Rojiani A, Siemann DW: Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: Effects on radiation therapy. Int J Radiat Oncol Biol Phys (1998) 42(4):899-903.
40. Tozer GM, Prise VE, Wilson J, Locke RJ, Vojnovic B, Stratford MRL, Dennis MF, Chaplin DJ: Combretastatin A-4 phosphate as a tumor vascular-targeting agent: Early effects in tumors and normal tissues. Cancer Res (1999) 59(7):1626-1634.
41. Horsman MR, Ehrnrooth E, Ladekarl M, Overgaard J: The effect of combretastatin A-4 disodium phosphate n a C3H mouse mammary carcinoma and a variety of murine spontaneous tumours. Int J Radiat Oncol Biol Phys (1998) 42(4):895-898.
42. Hori K, Saito S, Nihei Y, Suzuki M, Sato Y: Antitumor effects due to irreversible stoppage of tumor tissue blood flow: Evaluation of a novel combretastatin A-4 derivative, AC7700. Jpn J Cancer Res (1999) 90(9):1026-1038.
43. Murata R, Siemann DW, Overgaard J, Horsman MR: Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumours. Radiother Oncol (2001) 60(2):155-161.
44. Siemann DW, Rojiani AM: Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys (2002) 53(1):164-171.
45. Grosios K, Holwell SE, McGown AT, Pettit GR, Bibby MC: In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer (1999) 81(8):1318-1327.
46. Galbraith SM, Chaplin DJ, Lee F, Stratford MR, Locke RJ, Vojnovic B, Tozer GM: Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res (2001) 21(1A):93-102. Description of of mechanism of action of tubulin-binding based vascular targeting agents.
47. Kanthou C, Tozer GM: The tumor vascular targeting agent combrestatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood (2002) 99(6):2060-2069.
48. Wilson WR, Li AE, Cowan DSM, Siim BG: Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Int J Radiat Oncol Biol Phys (1998) 42(4):905-908.
49. Horsman MR, Murata R, Breidahl T, Nielsen FU, Maxwell RJ, Stodkiled-Jorgensen H, Overgaard J: Combretastatins novel vascular targeting drugs for improving anti-cancer therapy. Combretastatins and conventional therapy. Adv Exp Med Biol (2000) 476:311-323.
50. Siemann DW, Shi W: Targeting the tumor blood vessel network to enhance the efficacy of radiation therapy. Semin Radiat Oncol (2002): in press.
51. Landuyt W, Ahmed B, Nuyts S, Theys J, Op De Beeck M, Rijnders A, Anne J, Van Oosterom A, Can Den Bogaert W, Lambin P: In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment. Int J Radiat Oncol Biol Phys (2001) 49(2):443-450.
52. Horsman MR, Murata R: Combination of vascular targeting agents with thermal or radiation therapy. Int J Radiat Oncol Biol Phys (2002): in press. Enhanced antitumor efficacy resulting from the combination of radiation or hyperthermia and vascular targeting agents.
53. Murata R, Siemann DW, Overgaard J, Horsman MR: Improved tumor response by combining radiation and the vascular damaging drug 5,6-dimethylxanthenone-4-acetic acid. Radiat Res (2001) 156(5 Pt 1):503-509.
54. Li L, Rojiani AM, Siemann DW: Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi's sarcoma. Acta Oncol (2002) 41(1):91-97.
55. Siemann DW, Mercer E, Lepler SE, Rojiani AM: Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer (2002) 99(1):1-6. Describes the therapeutic benefit achieved when combining DMXAA or CA4P with conventional anticancer drugs.
56. Siemann DW, Rojiani AM: Anti-tumor efficacy of conventional anticancer drugs in enhanced by the vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys (2002): in press.